Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, double dummy, multicenter Phase 3 study of oral TR-701 FA 200 mg once daily for 6 days versus oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults.

Approximately 75 to 100 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment


Clinical Trial Description

The primary objective is to determine the noninferiority in the early clinical response rate of 6 day oral TR-701 FA compared with that of 10-day oral linezolid treatment at the 48-72 Hour Visit in the ITT analysis set in patients with ABSSSI. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01170221
Study type Interventional
Source Trius Therapeutics LLC
Contact
Status Completed
Phase Phase 3
Start date August 15, 2010
Completion date September 30, 2011

See also
  Status Clinical Trial Phase
Completed NCT01421511 - TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Active, not recruiting NCT02572791 - Staph Household Intervention for Eradication (SHINE) Phase 4
Completed NCT01984684 - Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT02796716 - Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections N/A
Completed NCT01283581 - A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections Phase 2
Completed NCT01519492 - A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci Phase 2
Completed NCT02060513 - Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections N/A
Completed NCT01811732 - Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT03964493 - TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection Phase 2